Nod for new self-developed cancer drug
Print Edition
China has granted market access to a self-developed cancer drug, the National Medical Products Administration announced.
The drug, known as Brukinsa (zanubrutinib) in capsule form, was developed by the biotechnology company BeiGene.
It is for the treatment of adult patients with mantle cell lymphoma, who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The drug was approved through a priority review procedure and its marketing authorization holder should continue with the confirmatory clinical trials, according to the administration.
The approval of the drug will provide an important treatment option for Chinese patients with lymphoma.
Wu Xiaobin, president of BeiGene, said that the development of the drug has taken more than eight years and around 25 clinical trials have been carried out in more than 20 countries, involving in excess of 500 international clinical experts.
More than 1,700 patients have joined the clinical trials globally.
The approval of the drug also underlines China’s progress in developing innovative drugs, Wu noted.
In November last year, the drug received approval from the United States Food and Drug Administration as a treatment for MCL in adult patients who have received at least one prior therapy.
Wang Zhiwei, vice president of BeiGene, said the company’s production line in Suzhou, east China’s Jiangsu Province, has an annual output of 100 million capsules, which can ensure the demand of the domestic market as well as the international market.
Lymphoma is a type of blood cancer which has seen increasing incidence both in China and the world.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
